Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Yurdaydin, Cihan; Abbas, Zaigham; Buti, Maria; Cornberg, Markus; Esteban, Rafael; Etzion, Ohad; Ganes, Edward; Gish, Robert; Glenn, Jeffrey; Hamids, Saeed; Heller, Theo; Koh, Christopher; Lampertico, Pietro; Lurie, Yoav; Manns, Michael; Parana, Raymundo; Rizzetto, Mario; Urban, Stephan; Wedemeyer, Heiner; Wranke, A.; Borzacov, Pinheiro; Lobato, C.; Hamid, S.; Ceausu, E.; Dalekos, G.; Turcanu, A.; Niro, G.; Lubna, F.; Abbas, M.; Ingiliz, P.; Ferenci, P.; Vanwolleghem, T.; Hayden, T.; Dashdorj, N.; Motoc, A.; Hardtke, S.

doi:10.1016/j.jhep.2018.12.022

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Copy For Citation

Yurdaydin C., Abbas Z., Buti M., Cornberg M., Esteban R., Etzion O., ...More

JOURNAL OF HEPATOLOGY, vol.70, no.5, pp.1008-1015, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 70 Issue: 5
Publication Date: 2019
Doi Number: 10.1016/j.jhep.2018.12.022
Journal Name: JOURNAL OF HEPATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1008-1015
Keywords: Hepatitis D, Treatment endpoints, Surrogate marker, New treatment approaches, PEGYLATED INTERFERON THERAPY, D-VIRUS, B-VIRUS, CLINICAL-TRIAL, MYRCLUDEX B, OPEN-LABEL, HDV, INFECTION, LONAFARNIB, RNA
Ankara University Affiliated: Yes

Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials. (C) 2018 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.